Mission statement:
NMTB’s purpose is to facilitate exchange of knowledge on ongoing and upcoming early phase 1-2 oncology trials for adult solid tumors. Phase 3 trials with select molecular alterations as well as early access / compassionate use programs can also be discussed.
NMTB will work to create a network and infrastructure for clinicians to facilitate cross-border referrals for such trials and early access programs.
NMTB will work to exchange knowledge on molecular targets and share molecular diagnostic pipeline updates, e.g. on DNA variants, structural variants, RNA expression, copy number alterations and the like.
NMTB will work to increase awareness of the Nordic region as an attractive region for conducting clinical trials through interaction with public and private partners.
NMTB will work to facilitate knowledge to overcome barriers for regulatory approval and site activation in clinical trials.
Please contact us if you have any questions
National coordinators:
Denmark – Martin Højgaard, Dept. Of Oncology, Rigshospitalet (martin.hoejgaard@regionh.dk)
Finland – Katriina Jalkanen, Clinical Trial Unit, Helsinki University Hospital (katriina.jalkanen@hus.fi)
Iceland – Gudbjorg Jonsdottir, Landshospitali (gudbjons@landshospitali.is)
Norway – Gro Live Fagereng, Oslo University Hospital (gfageren@ous-hf.no)
Sweden – Ana Carniero, Clinical Trials Unit, Lund University Hospital (ana.carniero@med.lu.se)
Inquiries:
For legal og logistic reasons we cannot reply to, nor advice on, specific patient or case related inquiries,
We recommend that patients and/or caregivers direct questions regarding treatment and testing to their treating physician.